MART-1 (27-35) (human)

O=C(N[C@@H](C)C(NCC(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N

[1]Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994 Jul 1;180 (1) :347-52. |[2]Nolte A, et al. Allogeneic Cell Therapy with Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Malignant Melanoma[M]//Transplantation in Hematology and Oncology II. Springer, Berlin, Heidelberg, 2003: 37-40.